Health condition
Renal rare tumours (chromophobe, papillary)
Non-clear-cell kidney cancers - papillary, chromophobe and rarer types - make up a quarter of renal cancers and differ from the common clear cell form in behaviour, drug response and inherited associations; subtype-specific management is the point.
Why trust this guide
- 01
Editorial team
Written by our editorial team from the UK sources listed on each page.
- 02
Sourced from guidance
Checked against current NHS and UK specialist society guidance at the time of review.
- 03
Current for 2026
Reviewed on 2026-09-27 with the next review scheduled for 2027-09-27.
Key facts
The essentials at a glance.
The symptoms to recognise, when to seek help, which specialist to see, and what treatment usually involves.
-
Chromophobe carcinoma generally carries an excellent prognosis after surgery
-
Papillary cancer has two behavioural patterns, and MET-driven cases have targeted options
-
Several subtypes track with inherited syndromes (HLRCC, Birt-Hogg-Dubé) warranting genetics review
-
Immunotherapy and cabozantinib-based regimens are reshaping advanced non-clear-cell treatment
Understanding the condition
What it is and what happens next.
What causes it, how it is diagnosed, and the treatment routes available in the UK.
What it is and how it feels
Kidney cancer’s standard narrative is written around clear cell carcinoma, yet the pathology report often says otherwise: papillary tumours - sometimes multiple and bilateral - or chromophobe carcinoma, whose bland behaviour after complete excision approaches that of benign disease. The distinctions carry consequences beyond prognosis: aggressive-variant papillary cancer in a young person raises the question of hereditary leiomyomatosis (HLRCC), and multiple chromophobe or hybrid tumours suggest Birt-Hogg-Dubé syndrome.
Diagnosis and treatment routes
Localised disease of any subtype is treated surgically, with partial nephrectomy preferred where feasible and active surveillance legitimate for small masses in the frail. Advanced non-clear-cell disease historically borrowed clear cell drugs with weaker results; dedicated trials have since established cabozantinib and immunotherapy combinations as credible standards, with MET inhibitors for the biologically defined papillary subset. Subtype confirmation by specialist uropathology - and genetics referral where patterns suggest syndrome - are the two quiet steps that most often change the plan. If you are waiting for results or want a second opinion on a proposed plan, a private consultation with a specialist who treats this condition regularly can usually be arranged quickly, and most will review your existing scans, biopsy reports and MDT correspondence.
Seeing a specialist
Who to see, and how quickly you can be seen.
The specialist for this condition is usually a consultant urologist. Your GP can refer you on the NHS, or you can arrange a private consultation directly.
A quiet reminder
This guide is for information, not medical advice.
Your GP knows your history and can tell you which parts apply to you. If in doubt, see them - and seek urgent care for any of the emergency symptoms described above.
Frequently asked
Common questions about Renal rare tumours (chromophobe, papillary).
Quick, plain-English answers to what people ask us most.
-
What are rare renal tumours like chromophobe and papillary kidney cancer?
Non-clear-cell kidney cancers - including papillary, chromophobe and rarer subtypes - make up about a quarter of kidney cancers and differ from the common clear cell form in how they behave and respond to treatment.
-
How do rare kidney cancer subtypes differ from clear cell kidney cancer?
These subtypes often grow more slowly and can respond differently to standard treatments used for clear cell kidney cancer, meaning accurate subtyping through pathology review is important for choosing the right treatment.
-
What are the symptoms of rare kidney cancer subtypes?
Symptoms are similar to other kidney cancers - often none in early stages, with blood in the urine, flank pain or a mass appearing as the tumour grows, frequently found incidentally on imaging.
-
How are rare renal tumour subtypes diagnosed?
Diagnosis requires careful pathology review, sometimes including specialist molecular testing, to correctly distinguish these subtypes from clear cell kidney cancer and from each other, since this affects treatment choice and prognosis.
-
How are chromophobe and papillary kidney cancers treated?
Surgery remains the mainstay for localised disease, similar to clear cell kidney cancer, but for advanced disease, treatment selection differs since these subtypes can respond less well to some standard clear cell treatments, making specialist oncology input important.
-
Are rare kidney cancer subtypes more or less aggressive than clear cell?
It varies by subtype - chromophobe tumours tend to behave less aggressively on average, while some rarer subtypes can behave more aggressively, which is why accurate subtyping matters for prognosis and treatment planning.
-
When should I seek a specialist opinion for a rare kidney cancer diagnosis?
Ask for referral to a urologist or oncologist with specific experience in non-clear-cell kidney cancers, given how treatment can differ. A private consultant urologist can typically be seen within about two weeks.